BMEA Quote, Financials, Valuation and Earnings

Crinetics Pharmaceuticals has a net margin of -- compared to Biomea Fusion's net margin of -18560.15%. Biomea Fusion's return on equity of -- beat Crinetics Pharmaceuticals's return on equity of -42.43%.

Biomea Fusion has a consensus price target of $40.56, signalling upside risk potential of 857.63%. On the other hand Crinetics Pharmaceuticals has an analysts' consensus of $75.07 which suggests that it could grow by 40.32%. Given that Biomea Fusion has higher upside potential than Crinetics Pharmaceuticals, analysts believe Biomea Fusion is more attractive than Crinetics Pharmaceuticals.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Crinetics Pharmaceuticals has a beta of 0.597, suggesting its less volatile than the S&P 500 by 40.297%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Crinetics Pharmaceuticals pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Crinetics Pharmaceuticals quarterly revenues of $399K. Biomea Fusion's net income of -$32.8M is higher than Crinetics Pharmaceuticals's net income of -$76.8M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Crinetics Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus -- for Crinetics Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of -- compared to Biomea Fusion's net margin of -4444.57%. Biomea Fusion's return on equity of -- beat iBio's return on equity of -148.3%.

Biomea Fusion has a consensus price target of $40.56, signalling upside risk potential of 857.63%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Biomea Fusion has higher upside potential than iBio, analysts believe Biomea Fusion is more attractive than iBio.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Biomea Fusion's net income of -$32.8M is lower than iBio's net income of -$4M. Notably, Biomea Fusion's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Biomea Fusion's net margin of -49.65%. Biomea Fusion's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Biomea Fusion has a consensus price target of $40.56, signalling upside risk potential of 857.63%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that Biomea Fusion has higher upside potential than NovaBay Pharmaceuticals, analysts believe Biomea Fusion is more attractive than NovaBay Pharmaceuticals.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Biomea Fusion's net income of -$32.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Biomea Fusion's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Biomea Fusion's net margin of -2357.27%. Biomea Fusion's return on equity of -- beat Palatin Technologies's return on equity of --.

Biomea Fusion has a consensus price target of $40.56, signalling upside risk potential of 857.63%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Biomea Fusion, analysts believe Palatin Technologies is more attractive than Biomea Fusion.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Biomea Fusion's net income of -$32.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.